LipoScience is an in vitro diagnostic company pioneering a new field of personalized diagnostics based on nuclear magnetic resonance, or NMR, technology. Our first diagnostic test, the NMR LipoProfile test, is cleared by the U.S. Food and Drug Administration (FDA), and directly measures the number of low density lipoprotein, or LDL, particles in a blood sample, providing physicians and their patients with actionable information to personalize management of risk for heart disease. To date, over 9 million NMR LipoProfile tests have been ordered. Our FDA-approved automated clinical analyzer, the Vantera system, requires no previous knowledge of NMR technology to operate and has been designed to significantly simplify complex technology through ease of use and walk-away automation.
LipoScience is driving toward becoming a clinical standard of care by decentralizing its technology and expanding its menu of personalized diagnostic tests to address a broad range of metabolic and other diseases.
Headquartered in Raleigh, North Carolina, LipoScience employs approximately 200 employees in the United States. The Company’s Common Stock is listed on the NASDAQ Global Market under the trading symbol “LPDX”.
05/21/13 at 12:00 PM ET
LipoScience Presents at UBS Global Healthcare Services Conference